Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PainChek (PCK) has signed a $5 million national trial grant agreement with the Department of Health
  • The grant will allow the company to conduct a national trial of its pain identification app alongside Australian’s with dementia living in aged care facilities
  • Painchek hopes to improve the diagnosis and management of pain in people with dementia
  • Enrolment for the program began in September 2019 and the agreement term will end on December 31, 2020
  • PainChek is up a slight 3.49 per cent this morning with shares trading for 22.3 cents apiece

PainChek (PCK) has signed a $5 million national trial grant agreement with the Department of Health

The company will use the grant to conduct a national trial of a pain identification smart-phone application, PainChek, for Australian’s with dementia living in residential aged care facilities.

The objectives of the grant are to provide access to PainChek technology for people living with dementia, collect relevant data on the use of PainChek in practice, and to evaluate the efficacy of the software.

PainChek is a fast and simple solution that uses the smartphone camera to record a short video of the person’s face and then analyse it using facial recognition analytics.

It automatically recognises facial muscle movements that indicate pain and then takes note of them.

The caregiver then uses the software to record observations of pain-related behaviour such as how the person is moving and vocalising pain.

PainChek then calculates an overall pain score and stores the results allowing the caregiver to monitor the effect of medication and treatment over time.

Just yestereday, PainChek confirmed its first order from the U.K. providing 1000 units of its software to Person Centred Software U.K.

The intended outcome of this grant is to improve diagnosis and management of pain in people living with dementia in residential aged care.

The $5 million consists of a $500,000 payment on execution of the agreement to support the development of training materials, in addition to an evaluation report and $4.4 million for the provision of 100,000 PainChek licenses.

The remaining $100,000 is earmarked for the delivery of an evaluation report at the end of the contract term.

PainChek began enrolling residential aged facilities in the Government grant program in September 2019 after finalising the terms, conditions and internal sign-off within the Department of Health.

The agreement term ends on December 31, 2020.

PainChek is up a slight 3.49 per cent this morning with shares trading for 22.3 cents apiece at 11:30 am AEDT.

PCK by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.